Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients

Bone Marrow Transplantation

Volumn 23, Issue 7, 1999, Pages 697-703

  Noskin, G ^a   Pietrelli, L ^b   Gurwith, M ^b   Bowden, R ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ALZA CORPORATION   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

ABCD; Amphotericin B cholesteryl sulfate for injection; Amphotericin B colloidal dispersion; Fungal infection; Marrow transplant; Nephrotoxicity

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHILD; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYCOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; SCHOOL CHILD;

EID: 0032950438     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701630     Document Type: Article

References (28)

1. Wingard JR, Beals SU, Santos GW et al. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987; 2: 175-181.
2. Karabinis A, Hill C, Leclercq B et al. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988; 26: 429-432.
3. Sable CA, Donowitz GR. Infection in bone marrow transplant recipients. Clin Infect Dis 1994; 18: 273-281.
4. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12: 1147-1201.
5. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 845-851.
6. Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infection in patients with acute leukemia. Ann Int Med 1993; 118: 495-503.
7. Terrell CL, Hughes CE. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 1992; 67: 69-91.
8. Clements JS, Peacock JE. Amphotericin B revisited: reassessment of toxicity. Am J Med 1990; 88: 5-22N-5-27N.
9. Hoitsma AJ, Wetzels JF, Koene RA. Drug-induced nephrotoxicity. Drug Safety 1991; 6: 131-147.
10. Hanson HL, Stevens DA. Comparison of the antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother 1992; 36: 486-488.
11. Clemons KV, Stevens DA. Comparison of Fungizone, AMPHOTEC, AmBisome and Abelcet against systemic murine cryptococcosis. Antimicrob Agents Chemother 1998; 42: 899-902.
12. White MH, Bowden RA, Sandler E et al. Amphotericin B colloidal dispersion (ABCD) vs amphotericin B (AmB) in the empiric treatment of febrile neutropenic patients. Blood 1996; 88 (Suppl. 1): (Abstr. 1196).
13. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995; 21: 1145-1153.
14. Fielding RM, Smith PC, Wang LH et al. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 1991; 35: 1208-1213.
15. Fielding RM, Singer AW, Wang LH et al. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 1991; 36: 299-307.
16. Allende MC, Lee JW, Francis P et al. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994; 38: 518-522.
17. White MH, Anaissie EJ, Kusne S et al. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24: 635-642.
18. Bowden RA, Cays M, Gooley T et al. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996; 173: 1208-1215.
19. Anaissie EJ, Mattiuzzi GN, Miller CB et al. Treatment of invasive fungal infections with amphotericin B colloidal dispersion (ABCD) in renally impaired patients. Antimicrob Agents Chemother 1998; 42: 606-611.
20. Medoff G, Dismukes WE, Pappagianis D et al. Evaluation of new antifungal drugs for the treatment of systemic fungal infections. Clin Infect Dis 1992; 15 (Suppl. 1): S274-S281.
21. Meyers JD, Atkinson K. Infection in bone marrow transplantation. Clin Hematol 1983; 12: 791-811.
22. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17: 10-13.
23. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-615.
24. Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine 1993; 72: 78-87.
25. Wald A, Leisenring W, van Burik J, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
26. Goodrich JM, Reed EC, Mori M et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-740.
27. Cruz JM, Peacock JE Jr, Loomer L et al. Rapid intravenous infusion of amphotericin B: a pilot study. Am J Med 1992; 93: 123-130.
28. Goodwin SD, Cleary JD, Walawander CA et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20; 755-761.